Ann: Agreement to acquire BCAL Diagnostics-SPX.AX, page-2

Spectrum Rare Earths Limited (“SPX” or the “Company”) is pleased to announce that it has entered into a binding Heads of Agreement (“HOA”) with BCAL Diagnostics Pty Limited (“BCAL Dx”) to acquire all of the issued capital in BCAL Dx.

About BCAL Diagnostics Pty Ltd (BCAL Dx)
BCAL Dx is a Sydney-based company that is developing a blood-based test for the presence of breast cancer. BCAL Dx believes, based on current data, that a test based on the technology (the BCAL test) has the potential to revolutionise breast cancer screening, diagnosis and monitoring on a global basis.
The current breast cancer screening market is dominated by imaging technologies such as mammography and ultrasound and there is currently no effective blood-based screening or diagnostic test for breast cancer on the market worldwide.



@heraclitus aquastion look's cracker.. Can't seem to work out the MC once all said & done.